RapidEK® (Recombinant Enterokinase)

RapidEK® (Recombinant Enterokinase)
Product Description

Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes. This includes Recombinant Enterokinase (RapidEK®). As a type 2 transmembrane serine protease, enterokinase is ideally suited for the biotechnological and biochemical removal of fusion proteins and cleavage of tags after purification. Produced by cells, enterokinase is responsible for the initial activation of pancreatic proteolytic proenzymes that catalyses the conversion of trypsinogen to trypsin. This means enterokinase is a very important enzyme in the biopharma and nutrition industry. We are ready to cater to biopharma needs for scale-up / commercial scale production.

Read more Show less

Paras Biopharmaceuticals Finland Oy

  • FI
  • 2018
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

Paras Biopharmaceuticals Finland Oy

  • FI
  • 2018
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile

More Products from Paras Biopharmaceuticals Finland Oy (4)

  • Anakinra Biosimilar Candidate

    Product Anakinra Biosimilar Candidate

    Paras Biopharmaceuticals has been intensively working on a Anakinra / IL1-RA biosimilar known as Kineret™) and has progressively achieved success. The company plans to mature good value within its Anakrina / IL1-RA asset and would like to highlight the following points / highlights to gauge your level of ...
  • RapidTEV® Protease (Recombinant TEV Protease)

    Product RapidTEV® Protease (Recombinant TEV Protease)

    Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes including Recombinant Tev Protease (RapidTEV®). RapidTEV® Protease is a site-specific protease that has been engineered for enhanced activity and greater stability. Due to its high specificity it is frequently used for the clea...
  • Rasburicase Biosimilar candidate

    Product Rasburicase Biosimilar candidate

    Paras Biopharmaceuticals has been intensively working on a Romiplostim biosimilar known as Elitek™ / Fasturtec™) and has progressively achieved success. The company plans to mature good value within its Rasburicase asset and would like to highlight the following points / highlights to gauge your level of ...
  • Romiplostim Biosimilar Candidate

    Product Romiplostim Biosimilar Candidate

    Due to the complex nature of the product, Paras Biopharmaceuticals has been intensively working on this complex drug (Nplate™) for over 6 years and has progressively achieved success. The company plans to mature good value within its Romiplostim asset (Biosimilar) and would like to highlight the following...